United States — United States Securities and Exchange Commission & Aldeyra Therapeutics

United States — United States Securities and Exchange Commission: The United States — United States Securities and Exchange Commission is the regulatory body under whose rules the class action lawsuit against Aldeyra Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 is being pursued.

Aldeyra Therapeutics: Aldeyra Therapeutics is the primary defendant in multiple class action lawsuits filed by various law firms, alleging that the company made false and misleading statements regarding the clinical trials of its drug candidate, reproxalap. The company's stock price fell significantly after the United States — Food and Drug Administration issued a Complete Response Letter for reproxalap.